LIVE WEBINAR
PRESENTED IN ENGLISH
Monday, June 8, 2026
Presentation8:00 pm ET - 9:00 pm ET
REGISTER NOW!
Thrombotic microangiopathy (TMA): When is it atypical hemolytic uremic syndrome (aHUS), and what do you do if it is?
In this interactive, discussion-based session, you’ll join an expert moderator to work through rich, clinically challenging patient cases in aHUS. With your peers, you’ll explore key decision points related to differential diagnosis, use of complement and genetic testing, treatment selection, and long-term management with complement directed therapy. The program will emphasize on shared clinical reasoning, real-world complexities, and practical strategies you can apply in your own practice.
In this interactive, discussion-based session, you’ll join an expert moderator to work through rich, clinically challenging patient cases in aHUS. With your peers, you’ll explore key decision points related to differential diagnosis, use of complement and genetic testing, treatment selection, and long-term management with complement directed therapy. The program will emphasize on shared clinical reasoning, real-world complexities, and practical strategies you can apply in your own practice.
XPresented bySusan Huang, PhD, MD, FRCPC, Nephrologist, London, ON
Learning Objectives
REGISTER NOW! - Differentiate aHUS from other thrombotic microangiopathies (TMAs) using appropriate clinical and biomarker tests, including genetic and complement testing
- Select and initiate appropriate anti-complement and supportive therapies in different patient populations
- Recognize when and how to continue, switch, or discontinue C5 inhibitor treatments as part of long-term patient management